tbuckley/cabot-search huggingface dataset:
Neurotransmitter Release
Authors: G Matthews
Journal: Annual Review of Neuroscience (1996)

Synaptic vesicle exocytosis is rapid and highly localized, which are features that arise from the organization of the presynaptic active zone, where vesicle fusion occurs. Colocalization of calcium channels with the proteins making up the vesicle docking machinery at the active zone, combined with the low affinity and high cooperativity of the calcium sensor for vesicle fusion, allows vesicles to fuse with short delay after a presynaptic action potential. Evidence suggests that the calcium concentration driving synaptic vesicle fusion corresponds to the high level (50-100 muM) achieved only within the microdomain of elevated calcium near the inner mouth of open calcium channels. Retrieval of synaptic vesicle membrane by endocytosis is also regulated by internal calcium but at much lower concentrations. Endocytosis occurs rapidly after exocytosis if internal calcium is near the basal level but is inhibited by elevated internal calcium (0.5-1.0 muM).
The Promise
Authors: Catriona M. McNeil
Journal: Annals of Internal Medicine (2019)

On Being a Patient6 August 2019The PromiseCatriona M. McNeil, MBBS, PhDCatriona M. McNeil, MBBS, PhDChris O'Brien Lifehouse, Camperdown, New South Wales, Australia (C.M.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M18-2403 Audio Reading - “The Promise” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “The Promise” by Catriona M. McNeil, MBBS, PhD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail I guess I always expected I would end up with Robbie. Not that I really mind.There was no real way to know in advance, but they knew the moment that Robbie was born. They saw it in his eyes, the way his tongue just sat there hanging out. The doctors kept looking at his hands.“He's a confirmed bachelor is our Patrick,” they all said when I moved back home to help. They would have been a bit worried about it until Robbie arrived. Then “confirmed bachelor” suited them just fine.Robbie was Mom's life, of course. She made ... Author, Article, and Disclosure InformationAffiliations: Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia (C.M.M.)Current Author Address: Catriona M. McNeil, MBBS, PhD, Chris O'Brien Lifehouse, 119–143 Missenden Road, Camperdown, NSW 2050, Australia; e-mail, catriona.[email protected]org.au. PreviousarticleNextarticle Advertisement Audio Reading - “The Promise” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “The Promise” by Catriona M. McNeil, MBBS, PhD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 6 August 2019Volume 171, Issue 3Page: 218-219KeywordsMilkNursesSmellSurgeonsThoraxTongueUlcersUrineVeinsWalking ePublished: 6 August 2019 Issue Published: 6 August 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Identification of a Novel Mode of Kinase Inhibitor Resistance: An F604S Exchange in FIP1L1-PDGFRA Modulates FIP1L1-PDGFRA Protein Stability in a SHP-2 and SRC-Dependent Manner
Authors: Sivahari Prasad Gorantla, Nikolas von Bubnoff, Christian Peschel, Justus Duyster
Journal: Blood (2011)
Phase I results of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
Authors: Nicole Concin, Ioana Braicu, Regina Berger, Sven Mahner, Jalid Sehouli, Alain G Zeimet, Eric Pujade-Lauraine, Philippe Alexandre Cassier, Ute Martha Moll, Hanno Ulmer, Karin Leunen, Christian Marth, Ignace Vergote, Isabelle Laure Ray-Coquard
Journal: Journal of Clinical Oncology (2016)

e17038 Background: Stabilized mutant p53 protein (mutp53) is a novel target in epithelial ovarian cancer (EOC). Due to aberrant conformation, mutp53 proteins depend on folding support by the Hsp90 chaperone. Hsp90 blockade induces degradation of mutp53, resulting in anti-tumor cytotoxicity and increased sensitivity to chemotherapeutics. The GANNET53 trial (EUDRACT 2013-003868-31,funded by the European Union FP7 grant agreement no 602602) tests the combination of G with P in platinum resistant EOC patients (pts). Methods: Eligiblepts had platinum resistant EOC, ≤ 4 prior chemotherapy lines and high grade histology. Weekly P (80 mg/m²) and increasing doses of G (100-150 mg/m²) were given i.v. on days 1, 8, 15 in a 28 day cycle until disease progression or unacceptable toxicity. End points were safety, determination of phase II dose, objective response rate and progression-free survival (PFS). Dose limiting toxicity (DLT) was defined as grade (gr) 4 toxicity (with exceptions) occurring in cycles 1 & 2. Results: Ten pts (median age 57 years, range 43-70) were enrolled. No DLT occurred in cohort 1 (4 pts treated with P + G 100 mg/m²), nor in cohorts 2 and 3 (6 pts treated with P + G 150mg/m²). The most frequent gr 1/2 AEs were diarrhea (n=8 pts), nausea (n=6), QTc prolongation (n=6), anemia (n=5), headache (n=5), abdominal and other pain (n=5), fatigue (n=3), neutropenia (n=3), anorexia (n=3) and dyspnea (n=3). Most frequent AEs ≥ gr 3 were diarrhea (n=3), anemia (n=3), neutropenia (n=2), and ascites (n=2). There were 5 related serious AEs, i.e. abdominal pain with vomiting (n=1), haemorrhagic shock from a duodenal ulcer (n=1, lethal), diarrhea (n=1), dyspnea (n=1) and acute cardiac insufficiency stage IV (n=1, recovered with sequelae). 2/10 (20%) pts showed partial response, 4/10 (40%) stable disease. Conclusions: The combination of ganetespib 150 mg/m² with paclitaxel 80 mg/m² once weekly for 3 out of 4 weeks was well tolerated and chosen for the ongoing randomized phase II trial. Clinical trial information: NCT02012192.
Cost-effectiveness of combined treatment for endocervical gonorrhea. Considering co-infection with Chlamydia trachomatis
Authors: A. E. Washington
Journal: JAMA (1987)

Three treatment regimens are currently recommended for penicillin-susceptible<i>Neisseria gonorrhoeae</i>infection of the cervix: ampicillin, tetracycline, and a combination of ampicillin and tetracycline. To evaluate the cost-effectiveness of these options, we developed a decision analysis model and analyzed the efficacy of each treatment in curing gonorrhea, as well as coexisting<i>Chlamydia trachomatis</i>infection, and in preventing subsequent pelvic inflammatory disease, ectopic pregnancy, and infertility. We included direct costs of medication and expenditures for management of unresolved infections and associated complications. Combination treatment is more than twice as cost-effective as tetracycline and seven times as cost-effective as ampicillin when the medical cost of managing pelvic inflammatory disease is considered. When the costs of ectopic pregnancies and infertility are included, the cost-effectiveness of combination treatment increases further. (<i>JAMA</i>1987;257:2056-2060)
Falling
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Discrimination of Human Lung Neoplasm from Normal Lung by Two Target Genes
Authors: H.-S. Hofmann
Journal: American Journal of Respiratory and Critical Care Medicine (2004)

Simple tools for discrimination of lung tissues can be useful in a fast machine-aided diagnosis, for example, by tumor-specific microarrays. We demonstrate that an easy ratio technique, based on the expression levels of only two genes differentially expressed in lung tumor and normal lung samples, allows discrimination of normal and neoplastic lung with a sensitivity of 100% and specificity of 90.5%. DNA microarray analysis of 99 lung tumor samples and 15 normal lung tissues revealed that receptor for advanced glycation end products (RAGE) mRNA is reduced fourfold (p = 7.8 × 10−11) and cyclin-B2 mRNA is upregulated twofold (p = 5.9 × 10−18) in lung carcinoma compared with normal lung. The microarray-calculated expression ratio of RAGE to cyclin-B2 was used in polymerase chain reaction analysis of 84 independent blinded samples to discriminate tumor and corresponding normal lung tissues. In 94.7% of the samples this quotient correctly distinguished non–small cell lung cancer from normal lung tissue, suggesting the RAGE/cyclin-B2 quotient as a potential means for diagnosis of lung cancer.
Reply
Authors: J Penston, K G Wormsley
Journal: Gut (1987)

SIR,-Drs Penston and Wormsley might have interpreted more satisfactorily the possible causes and effects of gastric ECL cell hyperplasia in achlorhydric subjects if they had considered the problem from an endocrinological rather than solely a gastroenterological point of view.The endocrine cells of the gut are scattered through the mucosa rather than gathered together in discrete glands, but
Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study.
Authors: D. B. Agus, W. M. Stadler, D. H. Shevrin, L. Hart, G. R. MacVicar, O. Hamid, J. D. Hainsworth, M. E. Gross, J. Wang, L. de Leon, D. MacLean, R. Dreicer
Journal: Journal of Clinical Oncology (2011)

4531 Background: The investigational agent TAK-700 is a selective 17,20 lyase inhibitor that downregulates androgenic steroid production in vitro and in vivo. Since phase I data in patients (pts) with mCRPC were promising, this open-label, multicenter study was expanded to gather additional data on safety and antitumor activity. Methods: The phase II portion of this study included four additional dose cohorts. Pts had received no prior chemotherapy, and had baseline testosterone <50 ng/dL, and prostate-specific antigen (PSA) ≥5 ng/mL. Here we report updated results. Results: 96 pts received TAK-700 300 mg BID (n=23), 400 mg BID + prednisone 5 mg BID (n=24), 600 mg BID + prednisone (n=26), or 600 mg QD (n=24). At data cut-off (15 Nov 2010), 50% of pts had withdrawn (including 13% due to AEs and 16% for disease progression). The most common AEs were fatigue (72%), nausea (44%), and constipation (31%); most common grade ≥3 AEs were fatigue (9%) and diarrhea (3%). PSA response rates (≥50% decrease) at 12 weeks were 63%, 52%, 41%, and 62% in the 300 mg BID, 400 and 600 mg BID + prednisone, and 600 mg QD groups. To date, of 43 pts with RECIST-evaluable disease, six had a partial response, 23 had stable disease, and nine had disease progression. At 12 weeks, median dehydroepiandrosterone sulfate (DHEA-S) and testosterone levels decreased from baseline in all groups (Table). Mean circulating tumor cell numbers also decreased in all groups. Conclusions: TAK-700 ≥300 mg BID appears active and well tolerated in pts with mCRPC, with similar efficacy ± prednisone. Preclinical data and changes in pharmacodynamic parameters in this study suggest selective 17,20 lyase inhibition. Final data will be reported. TAK-700 dose 300 mg BID 400 mg BID + prednisone 600 mg BID + prednisone 600 mg QD Median DHEA-S (µg/dL) Baseline 53.0 36.3 51.7 31.2 12 weeks 8.65 0.10 0.10 5.30 Median testosterone (ng/dL) Baseline 8.50 9.90 7.33 6.75 12 weeks 0.98 0.30 0.07 0.90
EPINEPHRIN IN ANESTHESIA
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE ADVANTAGES OF HOSPITAL INTERNESHIP.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Practical Bacteriology, Blood Work and Animal Parasitology.
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Inappropriate federal requirements for air control in hospital isolation rooms
Authors: F. S. Rhame
Journal: JAMA (1979)

ON FEB 14, 1947, there appeared in the<i>Federal Register</i>"General Standards" for the construction of hospitals. These standards were created at the request of Congress as part of the implementation of the Hill-Burton program, which provided federal funding for hospital construction. The standards were revised from time to time and in 1973 were retitled "Minimum Requirements of Construction and Equipment for Hospital Medical Facilities." The most recent version<sup>1</sup>was adopted on Oct 3, 1978. It applies to construction of new hospitals and renovation of existing hospitals. Since there is now almost no Hill-Burton money available for hospital construction or renovation, the requirements are used at the federal level only as a criterion for approval of Department of Housing and Urban Development loans to hospitals. However, 17 states have adopted them in their entirety, and most of the remaining states have adopted minimally modified versions.<sup>2(pp2-22)</sup>Although some of
Most Progressive Decade Foreseen for AMA
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Diagnosis and Treatment of Diabetes and the Use of High Carbohydrate Diets.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Heparin Osteoporosis.
Authors: George C. Griffith
Journal: Annals of Internal Medicine (1965)

s1 November 1965Heparin Osteoporosis.George C. Griffith, M.D., F.A.C.P., George Nichols Jr., M.D., John D. Asher, M.D.George C. Griffith, M.D., F.A.C.P.Search for more papers by this author, George Nichols Jr., M.D.Search for more papers by this author, John D. Asher, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-63-5-921_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTreatment of 117 men with up to 100 mg of heparin daily for 2 to 15 years in the prophylaxis of arteriosclerotic and thromboembolic disease was without apparent skeletal complications. When dosage was raised to 200 to 300 mg/day, six of ten men so treated developed marked osteoporosis by X ray, and multiple vertebral compression fractures within 2 years. Serum calcium, phosphorus, acid, and alkaline phosphatase were normal in all patients affected, as were rates of calcium, phosphorus, hydroxyproline excretion, and renal tubular resorption of phosphorus when tested. Parathyroid response to infusions of calcium and ethylenediamine-tetra-acetic acid was examined in... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Los Angeles, California, and Boston, Massachusetts PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByTargeting Biological Polyanions in Blood: Strategies toward the Design of Therapeutics 1 November 1965Volume 63, Issue 5Page: 921-922KeywordsCalciumExcretionHeparinOsteoporosisParathyroidPhosphatasesPhosphorusProphylaxis Issue Published: 1 November 1965 PDF DownloadLoading ...
Hazard of video games in patients with light-sensitive epilepsy
Authors: N. R. Dahlquist
Journal: JAMA (1983)

VIDEO games have become an epidemic form of amusement. Recently, two reports appeared from England of patients with epilepsy in whom playing video games precipitated seizures<sup>1,2</sup>(<i>Time</i>, July 19, 1982, p 67). To emphasize the particular hazard of video games for susceptible persons with light-sensitive epilepsy, we herein document the first record, to our knowledge, of a similar case in the United States. <h3>Report of a Case</h3> A 15-year-old boy played video games for one year before his first seizure. He had no medical problems until March 7, 1982. While the boy played an electronic game called "Combat," a friend noted that he acted as if he were in a daze and that his hand was twitching. When he returned home shortly thereafter, his mother noticed that he had lost his glasses, that he was "belligerent for the first time in his life," and that his mentation was slow.